Endocrine Abstracts

BackgroundSomatostatin analogues (SSA) (octreotide and lanreotide) are recommended as a first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of them are usually used in injection repeated every 4 weeks.The study objectiveWas to compare the way of SSA administration (injection performed by profession...